Abeona Therapeutics (ABEO) EBIT Margin (2011 - 2026)

Abeona Therapeutics' EBIT Margin history runs 13 years deep, the most recent figure standing at 264.14% for Q1 2026.

• In Q1 2026, EBIT Margin changed N/A year-over-year to 264.14%; the TTM figure through Mar 2026 stood at 80.22% (changed N/A YoY), while the FY2025 annual figure was 257.22%, changed N/A from the prior year.
• EBIT Margin was 264.14% for Q1 2026 at Abeona Therapeutics, down from 1503.82% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 1503.82% in Q4 2025 to a low of 19023.53% in Q4 2022.
• Historically, EBIT Margin has averaged 4362.19% across 4 years, with a median of 800.8% in 2022.
• Biggest YoY gain for EBIT Margin was 49926 bps in 2023; the steepest drop was 49926 bps in 2023.
• A 4-year view of EBIT Margin shows it stood at 19023.53% in 2022, then soared by 98 bps to 301.54% in 2023, then soared by 599 bps to 1503.82% in 2025, then plunged by 118 bps to 264.14% in 2026.
• The last three EBIT Margin figures came in at 264.14% (Q1 2026), 1503.82% (Q4 2025), and 5698.0% (Q2 2025), per Business Quant data.